Compare stocks

Molecular Partners AG is a biotechnology company specializing in the development of targeted protein therapeutics known as DARPin® molecules. These molecules are designed to modulate protein-protein interactions, providing potential treatments for a range of diseases, including cancer, ophthalmology, and infectious diseases. Founded in 2004, the company is headquartered in Zurich, Switzerland. Molecular Partners emphasizes its proprietary DARPin® technology as a competitive strength, offering advantages in selectivity and versatility compared to traditional antibodies. Its strategic focus includes advancing its pipeline of drug candidates through clinical trials and collaborating with major pharmaceutical firms for development and commercialization.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.